Pregnancy Is Heart History

0:00 · Opening

A pregnancy complication can disappear from the chart long before it stops being relevant to prevention. What changes when we ask about it?

Welcome to HEART RESERVE Clinical Conversations. I’m Lisa Zahakos, a physician assistant and founder of HEART RESERVE.

In this episode, we’ll follow Nina after delivery, Maria at a preventive visit, and Elena after a heart attack. These are fictional teaching cases for clinicians.

You can listen straight through, or use the chapters to return to a case. I’ll ask you to consider a few decisions and then walk through the reasoning. The activity page has the objectives, references and online questions.

0:35 · Nina: postpartum transition

Let’s start with Nina.

A postpartum handoff that needs an owner.

Nina is 34 and eight weeks postpartum. Her pregnancy was complicated by preeclampsia and gestational diabetes. She delivered at 34 weeks and is spending much of her time at the neonatal intensive care unit. An early blood-pressure check occurred, but the obstetric and primary care records do not show who owns her long-term follow-up. She is breastfeeding, has no acute symptoms, and has not completed postpartum glucose testing.

Ask before adding another task.

Nina says, “I thought the blood pressure problem ended when I delivered.” Ask what she was told, what testing has already happened, and what makes the next appointment difficult. Obtain the discharge summary, recorded blood pressures, pregnancy diagnoses, medicines and available laboratory results. Record the year and gestational age of the affected pregnancy and distinguish a confirmed diagnosis from the patient’s recollection.

A history of an adverse pregnancy outcome is a reason to assess present risk and maintain preventive care. It does not establish that Nina has coronary disease. Blood pressure, glycemia, lipid assessment, kidney status when indicated, tobacco exposure, physical activity, food access and sleep each contribute information. The 2026 American College of Cardiology postpartum pathway emphasizes coordinated follow-up for patients with or at risk for cardiovascular complications.

Here is the decision. Which plan best addresses the immediate care gap?

Pause here if you would like a moment to think it through.

The best next step in this case is: Arrange the postpartum glucose test, a feasible appointment and a named clinician to review and act on the result.

The recommended plan completes both the clinical task and the handoff. The alternative leaves the scheduling and responsibility gaps unresolved. The alternative delays an indicated postpartum glucose assessment. Ask what makes the visit difficult before finalizing the appointment.

Separate the urgent problem from the prevention visit.

Start with symptoms and the current blood pressure, not the list of incomplete screening tasks. Nina has no acute symptoms in the opening vignette. A later telephone call is a new clinical situation and requires a new urgency decision. Do not carry the reassurance from the first visit into the second encounter.

A useful history asks what happened, when it happened, how severe it was, and what remains unresolved. “Preeclampsia; delivery at 34 weeks; discharge summary requested” gives another clinician more information than “pregnancy problem.” Record patient-reported information as such while obtaining records. Avoid making the patient repeat her story to every service.

Time the right test.

American Diabetes Association recommends a fasting 75 gram oral glucose tolerance test at 4 to 12 weeks after gestational diabetes, interpreted with nonpregnancy criteria. In this early period, an A one C does not replace the recommended oral glucose tolerance test. Even a normal result does not end follow-up: ongoing screening for prediabetes or type 2 diabetes is recommended every 1 to 3 years.

Put the plan into the record.

The practice can arrange testing next week. Nina prefers a phone call after 3 PM. The primary care physician assistant accepts responsibility for reviewing the result and contacting her. In this worked example, the team checks for a result within two working days of the planned test and calls if the test was missed. These operational deadlines are examples, not guideline intervals.

Here is the decision. Before the test, Nina calls with new chest pain and difficulty breathing. What should the team do?

Pause here if you would like a moment to think it through.

The best next step in this case is: Arrange emergency assessment now and communicate her recent pregnancy and complications.

New postpartum chest pain and breathing difficulty warrant emergency assessment. An office appointment or home measurements must not delay that evaluation. Do not diagnose anxiety from this telephone description.

Teach the earlier postpartum window.

American College of Obstetricians and Gynecologists recommends blood-pressure evaluation no later than 7 to 10 days postpartum after a hypertensive disorder of pregnancy. The 2026 American College of Cardiology pathway specifies evaluation within 72 hours after discharge for patients with severe hypertension during the delivery hospitalization. Current severe blood pressure or concerning symptoms require urgent assessment, not a wait for that appointment. Nina’s eight-week visit continues the earlier surveillance.

A note another clinician can use.

“Preeclampsia and gestational diabetes in 2026, delivery at 34 weeks. Current symptoms reviewed. Early blood pressure follow-up verified. Postpartum oral glucose tolerance test arranged for the agreed date. the named clinician or team will review the result and contact the patient by the agreed date; if missed, the designated team member will call using the agreed contact method. Cardiovascular and metabolic follow-up booked for the agreed date.”

Add the actual blood pressure, medication reconciliation, renal findings when relevant and the patient’s next pregnancy plans. Confirm receipt of a referral rather than treating a sent referral as a completed visit.

Make a missed step visible.

An order, a completed test and an acted-on result are different events. In this illustrative workflow, the team records each separately. If the test is missed, ask what made it difficult and agree on a feasible next step. If the result is abnormal, the responsible clinician interprets it and arranges appropriate care; a reminder alone does not complete that task.

Use teach-back to check your explanation: “I want to be sure I explained this clearly. What is the next step, and who will contact you?” Ask how the patient wants to be reached. Coordinate appointments around infant care when possible. These workflow choices are practice examples, not prescribed guideline intervals.

Patient explanation.

“What happened in pregnancy is useful information for your health now. It gives us a reason to keep checking blood pressure and blood sugar and to review other heart risks. We can make a plan that works around the neonatal intensive care unit. I will tell you who is checking each result.”

The takeaway from this case: Start with current symptoms and urgency. Complete indicated postpartum testing. Name who reviews the result and who contacts the patient.

6:47 · Maria: midlife prevention

Now let’s move forward to Maria’s preventive visit.

A pregnancy history missing from midlife prevention.

Maria is 46 and attends a preventive visit. She has no known atherosclerotic cardiovascular disease or diabetes and no current symptoms. L D L cholesterol is 158 milligrams per deciliter, H D L cholesterol 49 milligrams per deciliter and triglycerides 145 milligrams per deciliter. She reports treated hypertension and a father who had a myocardial infarction at 49. She does not smoke. When asked directly, she describes severe preeclampsia with a delivery at 31 weeks. Her chart does not contain this history. She is not pregnant or breastfeeding and has no current pregnancy plans.

Here is the decision. How should the clinician use the newly elicited pregnancy history?

Pause here if you would like a moment to think it through.

The best next step in this case is: Document the history, complete the current assessment and discuss the full set of risk information.

Pregnancy history informs the assessment alongside current risk factors. The alternative omits relevant clinical context; The alternative invents an unvalidated adjustment. Obtain the missing inputs before using PREVENT atherosclerotic cardiovascular disease and do not assign a score from this abbreviated case.

What is missing before the risk calculation.

Maria belongs in a primary-prevention assessment because no atherosclerotic cardiovascular disease event is reported. The abbreviated vignette does not supply a complete current blood pressure, total cholesterol, body mass index or kidney assessment, and her medication record needs confirmation. Obtain the inputs required by the current validated calculator rather than substituting estimates. The PREVENT result is one part of a discussion that also considers reproductive risk markers and family history.

Keep the tasks distinct: record the pregnancy history, measure current risks, interpret the calculated estimate, then discuss treatment. Do not add an arbitrary percentage for preeclampsia or substitute the lipoprotein a concentration for a risk score. A low short-term estimate is also not permission to erase an important history from the record.

Use additional tests for a decision.

The 2026 dyslipidemia guideline recommends lipoprotein a measurement at least once in adulthood and selective apolipoprotein B assessment. lipoprotein a can reveal inherited risk not evident from a standard lipid panel. apolipoprotein B may help when cholesterol concentrations and atherogenic particle burden are discordant, including selected patients with metabolic disease or high triglycerides. A test is useful when its result changes the risk discussion or management.

Maria’s lipoprotein a returns at 165 nanomoles per liter. Record the laboratory units exactly. Avoid a fixed conversion between nanomoles per liter and milligrams per deciliter. Explain that the result supports closer attention to modifiable risks and family history; it is not a measurement of an arterial blockage. Do not promise that diet will normalize an inherited lipoprotein a level.

Build a feasible prevention plan.

Discuss blood-pressure control, a heart-healthy dietary pattern, activity appropriate to function, smoking avoidance and medication options when indicated. Ask what Maria can sustain. A registered dietitian can help translate dietary advice into meals, budget and cultural preferences. Document the next measurement and review date rather than ending with “lifestyle counseling provided.”

Reproductive plans can change the prescription.

Consider a separate 34-year-old patient with hyperlipidemia who takes a statin for primary prevention and now wants to become pregnant. Her case requires a different discussion from Maria’s. Confirm the medication, dose, indication, current pregnancy status, plans, contraceptive method and breastfeeding status. Avoid assuming that age alone establishes whether pregnancy is possible.

Here is the decision. Which counseling statement is most appropriate?

Pause here if you would like a moment to think it through.

The best next step in this case is: “Let’s review the exact medicine and indication with your prescriber before conception and agree on continuing cardiovascular care.”

Plan the treatment transition before conception with the prescriber. The alternative postpones the discussion; The alternative interrupts follow-up. Most pregnant patients discontinue statins, while very high-risk exceptions need individual specialist assessment. FDA advises against breastfeeding when ongoing statin treatment is required.

Questions that prevent an incomplete transition.

Why was this medicine prescribed, and how high is the patient’s current risk?

What does the current product information say for conception, pregnancy and lactation?

Who will agree on the timing, provide an alternative when needed and monitor the patient?

How will the plan be revisited after delivery or when breastfeeding ends?

The 2026 guideline generally defers most lipid-lowering therapies during conception, pregnancy and lactation. For established atherosclerotic cardiovascular disease or severe familial hypercholesterolemia, coordinate preventive cardiology or lipid expertise with obstetric care. Do not apply one washout rule to every drug, substitute an investigational therapy, or leave a high-risk patient without follow-up.

“Before you start trying to conceive, let’s review the medication with the clinician who prescribed it. We will agree on when to change it and how to look after your cholesterol and other risks during that time.”

Work through the treatment transition.

In the separate pregnancy-planning case, medication reconciliation starts with the actual drug and indication. The vignette does not name a product or dose, so do not invent either in the referral. Ask the prescriber to agree on a plan before conception, document who will explain it, and specify how it will be revisited. The pregnancy plan belongs in the prescribing record as well as the obstetric record.

The FDA removed the blanket pregnancy contraindication for statins while continuing to advise discontinuation in most pregnant patients. A small group with very high cardiovascular risk may require individual assessment. This change does not establish safety for every lipid drug or support routine statin use in pregnancy. When ongoing statin treatment is required after delivery, FDA advises against breastfeeding. Discuss feeding and cardiovascular treatment together.

Return to Maria.

Record Maria’s preferences, agreed prevention plan and the clinician who will reassess her response. Pregnancy history can improve the conversation without becoming a reason to overtest or to promise an unproven therapy.

The takeaway from this case: Record the pregnancy history without labeling it an atherosclerotic cardiovascular disease event. Complete current risk information before choosing treatment. Include reproductive plans in medication decisions.

13:17 · Elena: secondary prevention

For the third case, the clinical setting changes to secondary prevention.

Residual risk after a myocardial infarction.

Elena is 58, has type 2 diabetes, and had a myocardial infarction two years ago. She is postmenopausal. L D L cholesterol is 92 milligrams per deciliter while prescribed a high-intensity statin. She also reports preeclampsia many years earlier. The current decision is secondary prevention for established atherosclerotic cardiovascular disease. Her pregnancy history remains part of her record, but it does not replace the evidence-based treatment pathway for her myocardial infarction and diabetes.

Here is the decision. What is the best next step?

Pause here if you would like a moment to think it through.

The best next step in this case is: Confirm actual treatment use and response, address barriers, and choose additional evidence-based LDL lowering when indicated.

Establish what Elena actually takes and tolerates, then act on the appropriate L D L cholesterol goal. The alternative can miss access, adherence or adverse-effect problems. The alternative can prolong avoidable residual risk.

The guideline restores L D L cholesterol and non H D L cholesterol goals, including L D L cholesterol below 55 milligrams per deciliter for very-high-risk atherosclerotic cardiovascular disease. Confirm that Elena meets the full criteria before assigning this category; a prior myocardial infarction and diabetes alone do not establish multiple high-risk conditions. Apply the appropriate secondary-prevention pathway. Select additional treatment using the reduction needed, outcome evidence, safety, patient preference and access.

Maximally tolerated statin. Reason to discuss it: Foundational therapy in appropriate atherosclerotic cardiovascular disease care. Question before selecting: Actual use, symptoms, interactions and response?.

Ezetimibe. Reason to discuss it: An oral nonstatin option for additional LDL lowering. Question before selecting: Enough reduction for the patient’s goal?.

P C S K 9 monoclonal antibody. Reason to discuss it: Potent LDL lowering with cardiovascular outcomes evidence. Question before selecting: Access, administration and treatment burden?.

Bempedoic acid. Reason to discuss it: Oral option with outcomes evidence in studied statin-intolerant patients. Question before selecting: Indication, adverse effects, interactions and current label?.

Inclisiran. Reason to discuss it: LDL lowering through a different dosing approach. Question before selecting: Do not equate lipid efficacy with completed event-outcome evidence; check current data.

This comparison supports a treatment discussion; it does not establish a preferred product for every patient. Review current prescribing information before use.

Turn the L D L cholesterol result into a decision.

“Prescribed a high-intensity statin” is not the same as taking and tolerating it. Ask Elena to describe the medicine, dose and schedule she actually uses. Explore symptoms without dismissing them, and distinguish a clinical adverse effect from an affordability or refill problem. Review other causes of an inadequate lipid response and agree on a feasible regimen.

If actual use is confirmed and L D L cholesterol remains above the appropriate goal, discuss additional LDL-lowering therapy using the size of reduction needed, the evidence for her clinical setting and the practical burden of treatment. An oral agent and an injected agent may present different adherence and access issues. A lower laboratory value is useful only when the plan can be implemented and reviewed.

Benefits and harms belong in the same discussion.

CLEAR Outcomes reported more gout and cholelithiasis with bempedoic acid than placebo. The current FDA label warns about hyperuricemia and tendon injury and includes drug-interaction precautions. Ask about relevant history and review the exact current label before choosing treatment. These considerations accompany the cardiovascular result rather than disappearing because a trial met its endpoint.

Check the endpoint before recommending a medicine.

What the trials establish.

CLEAR Outcomes randomized 13,970 statin-intolerant patients with or at high cardiovascular risk. The primary composite occurred in 11.7 percent with bempedoic acid and 13.3 percent with placebo; hazard ratio 0.87, 95 percent confidence interval 0.79 to 0.96. These findings support an option for the studied population. They do not demonstrate safety in pregnancy or a benefit specifically after preeclampsia.

VESALIUS-cardiovascular studied evolocumab in patients with atherosclerosis or diabetes who had no previous myocardial infarction or stroke and found fewer first cardiovascular events than placebo. “No previous myocardial infarction or stroke” does not mean a healthy, low-risk population. Elena already has a prior myocardial infarction, so this trial should not be presented as a direct match to her history.

In September 2026, Novartis reported that pelacarsen lowered lipoprotein a in lipoprotein a HORIZON but did not meet the primary cardiovascular endpoint. This is a sponsor topline announcement; detailed methods and results require appraisal when available. Pelacarsen remains investigational in this report. Lowering a biomarker does not by itself establish clinical benefit, and one trial does not establish a class-wide conclusion.

Here is the decision. Elena asks whether a large fall in lipoprotein a means an investigational medicine will prevent her next myocardial infarction. Which answer is best?

Pause here if you would like a moment to think it through.

The best next step in this case is: “We need cardiovascular outcome results for the particular treatment and population while treating the risks we can address now.”

The alternative substitutes a biomarker response for a clinical outcome. The alternative overgeneralizes one trial to a whole class. Check the population, comparator, endpoint, absolute effect, uncertainty and harms.

Consider absolute effects as well as the headline.

In CLEAR Outcomes, subtracting 11.7 percent from 13.3 percent gives an absolute difference of 1.6 percentage points in the primary composite over the trial follow-up. The hazard ratio of 0.87 is a relative time-to-event comparison; it is not a 13-percentage-point absolute reduction. Neither number predicts Elena’s individual benefit. The studied population, background care and follow-up must remain attached to the estimate.

A composite endpoint combines several outcomes. Check which components changed, how harms were collected and whether follow-up was sufficient for the question. Do not infer a proven benefit for women with prior preeclampsia from an overall result unless an applicable analysis supports that claim. This activity uses trials to practice appraisal, not to create a pregnancy-specific treatment indication.

Elena’s next visit.

Agree on the treatment decision and review interval with Elena, document access arrangements, and name the clinician responsible for reassessing adherence, tolerance and laboratory response. Ask her to explain the plan in her own words. A prescription without access or follow-up is an incomplete plan.

The takeaway from this case: Distinguish prescribed treatment from actual use. Apply evidence from the appropriate patient population. Agree on an accessible treatment and follow-up plan.

20:34 · Take it into practice

Before you go, bring the three cases back to one question: what will you do differently at the next visit?

Ask what happened in pregnancy. Assess the risk that exists today. And make the next step someone’s responsibility.

You’ll find the source references, transcript and clinical resources beside this episode. To record your answers and complete the learning activity, return to the activity page for the questions and brief evaluation.

This has been HEART RESERVE Clinical Conversations. I’m Lisa Zahakos. Thank you for listening.